Research programme: small molecule therapeutics - Inventiva Pharma
Alternative Names: EHMT2 inhibitors - Inventiva Pharma; Enhancer of zeste homolog 2 inhibitors - Inventiva Pharma; euchromatic histone-lysine N-methyltransferase 2 - Inventiva Pharma; EZH2 inhibitors - Inventiva Pharma; G9a inhibitors - Inventiva Pharma; histone-lysine N-methyltransferase inhibitors - Inventiva Pharma; NSD2 inhibitors - Inventiva Pharma; TEAD/YAP inhibitors - Inventiva Pharma; YAP/TEAD inhibitors - Inventiva PharmaLatest Information Update: 26 Jun 2024
At a glance
- Originator Inventiva Pharma
- Developer Curie Institute; Inventiva Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors; Histone-lysine N-methyltransferase inhibitors; Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Mesothelioma
- Research Breast cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Skin cancer
- Discontinued Respiratory tract disorders
Most Recent Events
- 26 Jun 2024 Discontinued for Respiratory tract disorders in France (PO) (Inventiva pipeline; June 2024)
- 24 Jun 2024 Early research is ongoing in Breast cancer, Non-small-cell-lung-cancer, Multiple myeloma, Non-Hodgkin's lymphoma, Ovarian cancer and Skin cancer in France (PO)
- 24 Jun 2024 Preclinical development is ongoing in Mesothelioma in France (PO)